Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: We compared the post-treatment overall survival (OS) and recurrence-free survival (RFS) between patients with Child-Turcotte-Pugh (CTP) class-A and single small (≤3 cm) hepatocellular carcinoma (HCC) treated by surgical resection (SR) and radiofrequency ablation (RFA). Methods: We retrospectively analyzed 391 HCC patients with CTP class-A who underwent SR (n=232) or RFA (n=159) as first-line therapy for single small (≤3 cm) HCC. Survival was compared according to the tumor size (≤2 cm/2–3 cm) and the presence of cirrhosis. Inverse probability of treatment weighting (IPW) method was used to estimate the average causal effect of treatment. Results: The median follow-up period was 64.8 months (interquartile range, 0.1–162.6). After IPW, the estimated OS was similar in the SR and RFA groups (P=0.215), and even in patients with HCC of ≤2 cm (P=0.816) and without cirrhosis (P=0.195). The estimated RFS was better in the SR group than in the RFA groups (P=0.005), also in patients without cirrhosis (P<0.001), but not in those with HCC of ≤2 cm (P=0.234). The weighted Cox proportional hazards model with IPW provided adjusted hazard ratios (95% confidence interval) for OS, and the RFS after RFA versus SR were 0.698 (0.396– 1.232) (P=0.215) and 1.698 (1.777–2.448) (P=0.005), respectively. Conclusions: SR was similar for OS compared to RFA, but was better for RFS in patients with CTP class-A and single small (≤3 cm) HCC. The RFS was determined by the presence or absence of cirrhosis. Hence, SR rather than RFA should be considered in patients without cirrhosis to prolong the RFS, although there is no OS difference.
Abstract
Background/Aims: We compared the post-treatment overall survival (OS) and recurrence-free survival (RFS) between patients with Child-Turcotte-Pugh (CTP) class-A and single small (≤3 cm) hepatocellular carcinoma (HCC) treated by surgical resection (SR) and radiofrequency ablation (RFA). Methods: We retrospectively analyzed 391 HCC patients with CTP class-A who underwent SR (n=232) or RFA (n=159) as first-line therapy for single small (≤3 cm) HCC. Survival was compared according to the tumor size (≤2 cm/2–3 cm) and the presence of cirrhosis. Inverse probability of treatment weighting (IPW) method was used to estimate the average causal effect of treatment. Results: The median follow-up period was 64.8 months (interquartile range, 0.1–162.6). After IPW, the estimated OS was similar in the SR and RFA groups (P=0.215), and even in patients with HCC of ≤2 cm (P=0.816) and without cirrhosis (P=0.195). The estimated RFS was better in the SR group than in the RFA groups (P=0.005), also in patients without cirrhosis (P<0.001), but not in those with HCC of ≤2 cm (P=0.234). The weighted Cox proportional hazards model with IPW provided adjusted hazard ratios (95% confidence interval) for OS, and the RFS after RFA versus SR were 0.698 (0.396– 1.232) (P=0.215) and 1.698 (1.777–2.448) (P=0.005), respectively. Conclusions: SR was similar for OS compared to RFA, but was better for RFS in patients with CTP class-A and single small (≤3 cm) HCC. The RFS was determined by the presence or absence of cirrhosis. Hence, SR rather than RFA should be considered in patients without cirrhosis to prolong the RFS, although there is no OS difference.
참고문헌 (23)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Benson AB, "Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 19, pp.541~565 (2021)
- "EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma", Journal of Hepatology, 56(4), pp.908~943 (2012), Elsevier BV[DOI]
- Peter R. Galle, "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma", Journal of Hepatology, 69(1), pp.182~236 (2018), Elsevier BV[DOI]
- Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- Huang J, "A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria", Ann Surg, 252, pp.903~912 (2010)
- Feng K, "A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma", J Hepatol, 57, pp.794~802 (2012)
- Fang Y, "Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma", J Gastroenterol Hepatol, 29, pp.193~200 (2014)
- Chen MS, "A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma", Ann Surg, 243, pp.321~328 (2006)
- Jordi Bruix, "Management of hepatocellular carcinoma: An update", Hepatology, 53(3), pp.1020~1022 (2011), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Halpern EF, "Behind the numbers : inverse probability weighting", Radiology, 271, pp.625~628 (2014)
- Robins JM, "Marginal structural models and causal inference in epidemiology", Epidemiology, 11, pp.550~560 (2000)
- Pompili M, "Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey", J Hepatol, 59, pp.89~97 (2013)
- Teratani T, "Radiofrequency ablation for hepatocellular carcinoma in so-called highrisk locations", Hepatology, 43, pp.1101~1108 (2006)
- Chu HH, "Surgical resection versus radiofrequency ablation very early-stage HCC(≤2cm single HCC) : a propensity score analysis", Liver Int, 39, pp.2397~2407 (2019)
- Xu XL, "Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma : systematic review of randomized controlled trials with meta-analysis and trial sequential analysis", Radiology, 287, pp.461~472 (2018)
- 조주연, "Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma", Clinical and Molecular Hepatology, 22(4), pp.477~486 (2016), 대한간학회[DOI]
- Wakai T, "Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma < or =4 cm", World J Gastroenterol, 12, pp.546~552 (2006)
- Xu Q, "Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma : a meta-analysis of 16, 103 patients", Sci Rep, 4, pp.7252~ (2014)
- Molinari M, "Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation : a Markov model decision analysis", Am J Surg, 198, pp.396~406 (2009)
- Mair RD, "Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies", Clin Gastroenterol Hepatol, 10, pp.1412~1417 (2012)
- 김보현, "Epidemiology of liver cancer in South Korea", Clinical and Molecular Hepatology, 24(1), pp.1~9 (2018), 대한간학회